Associated medical consumption and costs during invasive fungal infection in acute myeloblastic leukemia patients in France
Jean‐Pierre Gangneux(Inserm), A Lafuma, B. Dupont(Délégation Paris 5), Denis Caillot, Philippe Moreau(Centre National de la Recherche Scientifique), Patricia Ribaud(Hôpital Saint-Louis), Pierre Berger, M. Michallet(Hospices Civils de Lyon), Raoul Herbrecht(Institut de Cancérologie Strasbourg)
HAL (Le Centre pour la Communication Scientifique Directe)
January 1, 2008
Cited by 3
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k